Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Enhanced hepatoprotection and bioavailability of silybin by coamorphous silybin-ursodeoxycholic acid

  • In: Poster Presentation
  • At: Stockholm (Sweden) (2017)
  • Type: Poster
  • Poster code: P-B-097-Tuesday
  • By: LIU, Dongchun (Shenyang Pharmaceutical University, department of Traditional Chinese Medicine, shenyang, China)
  • Co-author(s): Dongchun Liu: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
    Xiafei Shi: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
    Fang Wang: Faculty of functional food and wine, Shenyang Pharmaceutical University, Shenyang, China
    Huan Chen: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
    Dong Wang: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
    Yinghui Dai: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
    Xing Tang: Faculty of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
  • Abstract:

    Backgrounds

    Silybin (SLB), an antihepatopathy flavonolignan derived from the herb milk thistle (Silybum marianum), is poorly soluble and exists in form of microcrystals,resulting in poor oral bioavailability. Ursodeoxycholic acid (UDCA), a kind of hydrophilic bile acid, is most widely used for the treatment of cholestatic hepatopathies. Combined..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses